The association between reasons for first using cannabis, later pattern of use, and risk of first-episode psychosis: the EU-GEI case-control study.

Cannabis use path analysis psychotic disorders

Journal

Psychological medicine
ISSN: 1469-8978
Titre abrégé: Psychol Med
Pays: England
ID NLM: 1254142

Informations de publication

Date de publication:
Nov 2023
Historique:
pubmed: 2 5 2023
medline: 2 5 2023
entrez: 2 5 2023
Statut: ppublish

Résumé

While cannabis use is a well-established risk factor for psychosis, little is known about any association between reasons for first using cannabis (RFUC) and later patterns of use and risk of psychosis. We used data from 11 sites of the multicentre European Gene-Environment Interaction (EU-GEI) case-control study. 558 first-episode psychosis patients (FEPp) and 567 population controls who had used cannabis and reported their RFUC.We ran logistic regressions to examine whether RFUC were associated with first-episode psychosis (FEP) case-control status. Path analysis then examined the relationship between RFUC, subsequent patterns of cannabis use, and case-control status. Controls (86.1%) and FEPp (75.63%) were most likely to report 'because of friends' as their most common RFUC. However, 20.1% of FEPp compared to 5.8% of controls reported: 'to feel better' as their RFUC (χ Both FEPp and controls usually started using cannabis with their friends, but more patients than controls had begun to use 'to feel better'. People who reported their reason for first using cannabis to 'feel better' were more likely to progress to heavy use and develop a psychotic disorder than those reporting 'because of friends'.

Sections du résumé

BACKGROUND BACKGROUND
While cannabis use is a well-established risk factor for psychosis, little is known about any association between reasons for first using cannabis (RFUC) and later patterns of use and risk of psychosis.
METHODS METHODS
We used data from 11 sites of the multicentre European Gene-Environment Interaction (EU-GEI) case-control study. 558 first-episode psychosis patients (FEPp) and 567 population controls who had used cannabis and reported their RFUC.We ran logistic regressions to examine whether RFUC were associated with first-episode psychosis (FEP) case-control status. Path analysis then examined the relationship between RFUC, subsequent patterns of cannabis use, and case-control status.
RESULTS RESULTS
Controls (86.1%) and FEPp (75.63%) were most likely to report 'because of friends' as their most common RFUC. However, 20.1% of FEPp compared to 5.8% of controls reported: 'to feel better' as their RFUC (χ
CONCLUSIONS CONCLUSIONS
Both FEPp and controls usually started using cannabis with their friends, but more patients than controls had begun to use 'to feel better'. People who reported their reason for first using cannabis to 'feel better' were more likely to progress to heavy use and develop a psychotic disorder than those reporting 'because of friends'.

Identifiants

pubmed: 37129249
doi: 10.1017/S0033291723001071
pii: S0033291723001071
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

7418-7427

Subventions

Organisme : NIDA NIH HHS
ID : K01DA051759
Pays : United States
Organisme : Medical Research Council
ID : MR/W030608/1
Pays : United Kingdom
Organisme : NIDA NIH HHS
ID : K01DA051759
Pays : United States
Organisme : Wellcome Trust
ID : 101272/Z/12/Z
Pays : United Kingdom

Auteurs

Edoardo Spinazzola (E)

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College of London, London, UK.

Diego Quattrone (D)

Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.
National Institute for Health Research, Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College, London, UK.
South London and Maudsley NHS Mental Health Foundation Trust, London, UK.

Victoria Rodriguez (V)

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College of London, London, UK.

Giulia Trotta (G)

Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.

Luis Alameda (L)

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College of London, London, UK.
Service of General Psychiatry, Treatment and Early Intervention in Psychosis Program, Lausanne, University Hospital (CHUV), Lausanne, Switzerland.
Centro Investigacion Biomedica en Red de Salud Mental (CIBERSAM); Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocio, Departamento de Psiquiatria, Universidad de Sevilla, Sevilla, Spain.

Giada Tripoli (G)

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College of London, London, UK.
Biomedicine, Neuroscience and Advanced Diagnostic Department, Psychiatry Section, University of Palermo, Palermo, Italy.

Charlotte Gayer-Anderson (C)

Department of Health Service and Population Research, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Tom P Freeman (TP)

Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, UK.
National Addiction Centre, Institute of Psychiatry, King's College London, London, UK.

Emma C Johnson (EC)

Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.

Hannah E Jongsma (HE)

Psylife Group, Division of Psychiatry, University College London, London, UK.

Simona Stilo (S)

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College of London, London, UK.
Department of Mental Health and Addiction Services, ASP Crotone, Crotone, Italy.

Caterina La Cascia (C)

Biomedicine, Neuroscience and Advanced Diagnostic Department, Psychiatry Section, University of Palermo, Palermo, Italy.

Laura Ferraro (L)

Biomedicine, Neuroscience and Advanced Diagnostic Department, Psychiatry Section, University of Palermo, Palermo, Italy.

Daniele La Barbera (D)

Biomedicine, Neuroscience and Advanced Diagnostic Department, Psychiatry Section, University of Palermo, Palermo, Italy.

Antonio Lasalvia (A)

Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.

Sarah Tosato (S)

Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.

Ilaria Tarricone (I)

Department of Medical and Surgical Science, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, Bologna, Italy.

Giuseppe D'Andrea (G)

Department of Medical and Surgical Science, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, Bologna, Italy.

Michela Galatolo (M)

Department of Medical and Surgical Science, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, Bologna, Italy.

Andrea Tortelli (A)

Institut Mondor de recherché biomedicale, Creteil, France.
Etablissement Public de Sante Maison Blanche, Paris, France.

Ilaria Tagliabue (I)

Department of Medicine and Surgery, University of Milano Bicocca, Monza, Italy.
Department of Mental Health and Addiction Services, ASST Lecco, Lecco, Italy.

Marco Turco (M)

Department of Medicine and Surgery, University of Milano Bicocca, Monza, Italy.

Maurizio Pompili (M)

Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Center, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.

Jean-Paul Selten (JP)

Rivierduinen Institute for Mental Health Care, Leiden, The Netherlands.
Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, South Limburg Mental Health Research and Teaching Network, Maastricht University Medical Centre, Maastricht, The Netherlands.

Lieuwe de Haan (L)

Early Psychosis Section, AmsterdamUMC, Academic Medical Centre, University of Amsterdam, Meibergdreef 5, 1105 AZ Amsterdam, The Netherlands.

Paulo Rossi Menezes (P)

Department of Preventive Medicine, Faculdade de Medicina, Universidade of São Paulo, São Paulo, Brazil.

Cristina M Del Ben (CM)

Department of Preventive Medicine, Faculdade de Medicina, Universidade of São Paulo, São Paulo, Brazil.

Jose Luis Santos (JL)

Department of Psychiatry, Servicio de Psiquiatría Hospital "Virgen de la Luz", Cuenca, Spain.

Manuel Arrojo (M)

Department of Psychiatry, Psychiatric Genetic Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago, Spain.

Julio Bobes (J)

Department of Medicine, Psychiatry Area, School of Medicine, Universidad de Oviedo, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Oviedo, Spain.

Julio Sanjuán (J)

Department of Psychiatry, School of Medicine, Universidad de Valencia, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Valencia, Spain.

Miguel Bernardo (M)

Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital Clinic of Barcelona, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Biomedical Research Networking Centre in Mental Health (CIBERSAM), Barcelona, Spain.

Celso Arango (C)

Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM, CIBERSAM, Madrid, Spain.

James B Kirkbride (JB)

Reader; Psylife Group, Division of Psychiatry, University College London, London, UK.

Peter B Jones (PB)

Department of Psychiatry, University of Cambridge, Cambridge, UK.
CAMEO Early Intervention Service, Cambridgeshire & Peterborough NHS Foundation Trust, Cambridge, UK.

Michael O'Donovan (M)

Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.

Bart P Rutten (BP)

Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, South Limburg Mental Health Research and Teaching Network, Maastricht University Medical Centre, Maastricht, The Netherlands.

Jim Van Os (J)

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College of London, London, UK.
Rivierduinen Institute for Mental Health Care, Leiden, The Netherlands.
Department Psychiatry, Brain Centre Rudolf Magnus, Utrecht University Medical Centre, Utrecht, The Netherlands.

Craig Morgan (C)

Department of Health Service and Population Research, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Pak C Sham (PC)

Department of Psychiatry, Centre for PanorOmic Sciences, and State Key Laboratory of Brain and Cognitive Sciences, Li KaShing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.

Isabelle Austin-Zimmerman (I)

Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.

Zhikun Li (Z)

Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.

Evangelos Vassos (E)

Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.

Robin M Murray (RM)

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College of London, London, UK.

Marta Di Forti (M)

Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.
South London and Maudsley NHS Mental Health Foundation Trust, London, UK.
Research Foundation, National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London and the NIHR BRC at University College London, London, UK.

Classifications MeSH